Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Autografting

Randomized study of early hospital discharge following autologous blood SCT: medical outcomes and hospital costs

Bone Marrow Transplantation volume 47, pages 549–555 (2012)Cite this article

Abstract

We report the first randomized study comparing early hospital discharge with standard hospital-based follow-up after high-dose chemotherapy (HDCT) and PBSCT. Patients aged 18–65 years, with an indication of PBSCT for non-leukemic malignant diseases were randomly assigned between two arms. Arm A consisted of early hospital discharge (HDCT during hospitalization, discharge at day 0, home stay with a caregiver, outpatient clinic follow-up). In arm B patients were followed up as inpatients. In total 131 patients were analyzed (66 in arm A and 65 in arm B). Patient characteristics and hematological reconstitution were comparable between the two groups. In arm A, 26 patients were actually discharged early. Patients in group A spent fewer days in hospital (11 vs 12 days, P=0.006). This strategy resulted in a 6% mean cost reduction per patient when compared with the conventional hospital-based group. The early discharge approach within the French health system, while safe and feasible, is highly dependent on social criteria (caregiver availability and home to hospital distance). It is almost always associated with conventional hospital readmission during the aplasia phase, and limits cost savings when considering the whole population of patients benefiting from HDCT in routine clinical practice.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

References

  1. Le Corroller AG, Moatti JP . The economic evaluation of hematopoietic growth factors in high dose chemotherapy. Anti Cancer Drugs 1998; 9: 917–924.

    Article  CAS  PubMed  Google Scholar 

  2. Smith AM, Keating A . Peripheral blood progenitor cell transplantation: clinical, practical and economic considerations. J Hematother 1994; 3: 331–348.

    Article  CAS  PubMed  Google Scholar 

  3. Uyl-de Groot CA, Ossenkoppele GJ, van Riet AAPM, Rutten FFH . The costs of peripheral blood progenitor cell reinfusion mobilised by granulocyte colony-stimulating factor following high dose melphalan as compared with conventional therapy in multiple myeloma. Eur J Cancer 1994; 30A: 457–459.

    Article  CAS  PubMed  Google Scholar 

  4. Hartmann O, Le Corroller AG, Blaise D, Michon J, Philip I, Norol F et al. Peripheral blood stem cells and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized controlled trial. Ann Intern Med 1997; 126: 600–607.

    Article  CAS  PubMed  Google Scholar 

  5. Anastasia A, Giglio F, Mazza R, Sarina B, Todisco E, Bramanti S et al. Early discharge after high-dose melphalan and peripheral blood stem cell reinfusion in patients with hematological and non-hematological disease. Leuk Lymphoma 2009; 50: 80–84.

    Article  CAS  PubMed  Google Scholar 

  6. Fernandez-Aviles F, Carreras E, Urbano-Ispizua A, Rovira M, Martinez C, Gaya A et al. Case-control comparison of at-home to total hospital care for autologous stem-cell transplantation for hematologic malignancies. J Clin Oncol 2006; 24: 4855–4861.

    Article  PubMed  Google Scholar 

  7. Ferrara F, Palmieri S, Viola A, Copia C, Schiavone EM, De Simone M et al. Outpatient-based peripheral blood stem cell transplantation for patients with multiple myeloma. Hematol J 2004; 5: 222–226.

    Article  PubMed  Google Scholar 

  8. Freeman M, Vose J, Bennett C, Anderson J, Kessinger A, Turner K et al. Costs of care associated with high-dose therapy and autologous transplantation for non-Hodgkin's lymphoma: results from the University of Nebraska Medical Center 1989 to 1995. Bone Marrow Transplant 1999; 24: 679–684.

    Article  CAS  PubMed  Google Scholar 

  9. Frey P, Stinson T, Siston A, Knight SJ, Ferdman E, Traynor A et al. Lack of caregivers limits use of outpatient hematopoietic stem cell transplant program. Bone Marrow Transplant 2002; 30: 741–748.

    Article  CAS  PubMed  Google Scholar 

  10. Gluck S, des Rochers C, Cano C, Dorreen M, Germond C, Gill K et al. High-dose chemotherapy followed by autologous blood cell transplantation: a safe and effective outpatient approach. Bone Marrow Transplant 1997; 20: 431–434.

    Article  CAS  PubMed  Google Scholar 

  11. Jagannath S, Vesole DH, Zhang M, Desikan KR, Copeland N, Jagannath M et al. Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma. Bone Marrow Transplant 1997; 20: 445–450.

    Article  CAS  PubMed  Google Scholar 

  12. Leger C, Sabloff M, McDiarmid S, Bence-Bruckler I, Atkins H, Bredeson C et al. Outpatient autologous hematopoietic stem cell transplantation for patients with relapsed follicular lymphoma. Ann Hematol 2006; 85: 723–729.

    Article  PubMed  Google Scholar 

  13. McDiarmid S, Hutton B, Atkins H, Bence-Bruckler I, Bredeson C, Sabri E et al. Performing allogeneic and autologous hematopoietic SCT in the outpatient setting: effects on infectious complications and early transplant outcomes. Bone Marrow Transplant 2010; 45: 1220–1226.

    Article  CAS  PubMed  Google Scholar 

  14. Meisenberg BR, Miller WE, McMillan R, Callaghan M, Sloan C, Brehm T et al. Outpatient high-dose chemotherapy with autologous stem-cell rescue for hematologic and nonhematologic malignancies. J Clin Oncol 1997; 15: 11–17.

    Article  CAS  PubMed  Google Scholar 

  15. Peters WP, Ross M, Vredenburgh J, Hussein A, Rubin P, Dukelow K et al. The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer. Semin Oncol 1994; 21 (supl 7): 25–31.

    CAS  PubMed  Google Scholar 

  16. Rizzo JD, Vogelsang GB, Krumm S, Frink B, Mock V, Bass EB . Outpatient-based bone marrow transplantation for hematologic malignancies: cost saving or cost shifting? J Clin Oncol 1999; 17: 2811–2818.

    Article  CAS  PubMed  Google Scholar 

  17. Summers N, Dawe U, Stewart DA . A comparison of inpatient and outpatient ASCT. Bone Marrow Transplant 2000; 26: 389–395.

    Article  CAS  PubMed  Google Scholar 

  18. Mehta J, Dulley FL . Outpatient or inpatient stem cell transplantation: patria est ubicunque est bene? Leuk Lymphoma 2009; 50: 3–5.

    Article  PubMed  Google Scholar 

  19. Dix SP, Geller RB . High-dose chemotherapy with autologous stem cell rescue in the outpatient setting. Oncology (Huntingt) 2000; 14: 171–185; discussion 85–86, 91–92.

    CAS  Google Scholar 

  20. Peters WP, Ross M, Vredenburgh JJ, Hussein A, Rubin P, Dukelow K et al. The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer. Semin Oncol 1994; 21 (Suppl 7): 25–31.

    CAS  PubMed  Google Scholar 

  21. Rovira M . Outpatient management of autologous haematopoietic cell transplantation: the Barcelona experience. Presse Med 2004; 33: 479–481.

    Article  PubMed  Google Scholar 

  22. Westermann AM, Holtkamp MM, Linthorst GA, van Leeuwen L, Willemse EJ, van Dijk WC et al. At home management of aplastic phase following high-dose chemotherapy with stem-cell rescue for hematological and non-hematological malignancies. Ann Oncol 1999; 10: 511–517.

    Article  CAS  PubMed  Google Scholar 

  23. Stiff P, Mumby P, Miler L, Rodriguez T, Parthswarthy M, Kiley K et al. Autologous hematopoietic stem cell transplants that utilize total body irradiation can safely be carried out entirely on an outpatient basis. Bone Marrow Transplant 2006; 38: 757–764.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The study was supported by the French clinical research projects funding program (PHRC).

Author information

Authors and Affiliations

  1. Institut Paoli-Calmettes—Regional Center for Cancer Research and Treatment, Marseilles, France

    C Faucher, B Esterni, N Vey, A M Stoppa, C Chabannon, D Genre, P Viens & D Blaise

  2. INSERM, UMR 912, IRD, Epidemiology and Social Sciences Health care Systems and Society, SE4S, Marseilles, France

    A G Le Corroller Soriano & J P Moatti

  3. Université Aix Marseille, Marseilles, France

    A G Le Corroller Soriano, N Vey, C Chabannon, P Viens, J P Moatti & D Blaise

  4. INSERM UMR 891, Centre de Recherche en Cancérologie de Marseille, Marseille, France

    N Vey, C Chabannon & D Blaise

  5. Hotel Dieu, Nantes, France

    M Mohty

  6. Hopital Edouard Herriot, Lyon, France

    M Michallet

  7. Centre Jean Perrin et CHU d'estaing, Clermont-Ferrand, France

    J O Bay

  8. Centre d'Investigation Clinique (CIC) 9502, Marseilles, France

    D Genre & P Viens

  9. Institut National du Cancer (INCa), Boulogne Billancourt, France

    D Maraninchi

Authors
  1. C Faucher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A G Le Corroller Soriano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B Esterni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N Vey
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A M Stoppa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Chabannon
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Mohty
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Michallet
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J O Bay
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. D Genre
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. D Maraninchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. P Viens
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. J P Moatti
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. D Blaise
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C Faucher.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Faucher, C., Le Corroller Soriano, A., Esterni, B. et al. Randomized study of early hospital discharge following autologous blood SCT: medical outcomes and hospital costs. Bone Marrow Transplant 47, 549–555 (2012). https://doi.org/10.1038/bmt.2011.126

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2011.126

Keywords

  • auto-SCT
  • outpatient
  • cost

This article is cited by

Search

Advanced search

Quick links